Your browser doesn't support javascript.
loading
Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
Hamed, Alaa; An Haack, Kristina; Gwaltney, Chad; Baranowski, Eileen; Stewart, Andrew; Krupnick, Robert; Tyler, Margaret; Sparks, Susan; Paty, Jean.
Afiliação
  • Hamed A; Sanofi Genzyme, 50 Binney Street, Cambridge, MA, 02142, USA.
  • An Haack K; Sanofi Genzyme, Shanghai, China.
  • Gwaltney C; Gwaltney Consulting, Westerly, RI, USA.
  • Baranowski E; Sanofi Genzyme, 50 Binney Street, Cambridge, MA, 02142, USA.
  • Stewart A; Sanofi Genzyme, 50 Binney Street, Cambridge, MA, 02142, USA.
  • Krupnick R; IQVIA INC, New York City, NY, USA.
  • Tyler M; IQVIA INC, New York City, NY, USA.
  • Sparks S; Sanofi Genzyme, 50 Binney Street, Cambridge, MA, 02142, USA. Susan.Sparks@sanofi.com.
  • Paty J; IQVIA INC, New York City, NY, USA.
Orphanet J Rare Dis ; 16(1): 428, 2021 10 12.
Article em En | MEDLINE | ID: mdl-34641935
ABSTRACT

BACKGROUND:

Late-onset Pompe Disease (LOPD) is a rare, heterogeneous disease manifested by a range of symptoms varying in severity. Research establishing the frequency of these symptoms and their impact on patients' daily lives is limited. The objective of this study was to develop a conceptual model that captures the most relevant symptoms and functional limitations experienced by patients with LOPD, to inform the development of new patient-reported outcome (PRO) tools.

METHODS:

A preliminary conceptual model was constructed following a literature review and revised through interviews with expert clinicians to identify important and relevant concepts regarding symptoms and impacts of LOPD. This preliminary model informed the development of a qualitative patient interview guide, which was used to gather the patient perspective on symptoms and impacts relating to LOPD or its treatment (including symptom/impact frequency and levels of disturbance). Patient interviews aided further refinement of the conceptual model. The findings from the patient interviews were triangulated with the literature review and clinician interviews to identify the most relevant and significant effects of LOPD from the patient perspective.

RESULTS:

Muscle weakness, fatigue, pain, and breathing difficulties (especially while lying down) were the most common and highly disturbing symptoms experienced by patients. Limitations associated with mobility (e.g., difficulty rising from a sitting position, getting up after bending) and activities of daily living, (e.g., reduced ability to participate in social/family activities or work/study) were the most frequently reported impacts with the highest levels of disturbance on the patient's daily life. These identified symptoms and impacts were included in the new conceptual model of disease.

CONCLUSIONS:

This qualitative patient interview study, also informed by a literature review and clinician interviews, identified the most frequent and relevant symptoms and the functional impact of LOPD on patients. The study interviews also captured the patient-preferred language to describe symptoms and impacts of LOPD. The results from this study can be used to develop future PRO instruments that are tailored to the specific symptoms and impacts experienced by patients with LOPD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Depósito de Glicogênio Tipo II Tipo de estudo: Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Depósito de Glicogênio Tipo II Tipo de estudo: Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article